AptameXTM, Achiko's breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman SehatTM ("Health Buddy").
Achiko AG through PT Achiko Medika Indonesia ("Achiko", the "Company"), is pleased to announce that the Ministry of Health of the Republic of Indonesia has granted product and registration approval for its proprietary low-cost, rapid Covid-19 diagnostic test, AptameXTM, alongside its sister digital passporting service, Teman SehatTM ("Health Buddy"). Achiko's 50%-subsidiary, PT Achiko Medika Indonesia, and PT Indofarma TBK ("Indofarma) have entered into an agreement to manufacture AptameXTM and have received product registration approval in Indonesia.
The approval opens the door to the rapid scale-up of production and sale in Indonesia
The approval opens the door to the rapid scale-up of production and sale of Achiko's AptameXTM test kits in Indonesia. Available at an affordable price, AptameXTM provides millions of Indonesian residents with access to accurate diagnostic testing for Covid-19, enabling the country to more effectively control and contain the pandemic. Indonesia passed 50,000 daily Covid-19 cases in mid-July, amid the spread of the Delta variant in Southeast Asia.